- Home
- SELF vs LITS Comparison
SELF vs LITS Comparison
Compare SELF & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | LITS |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 40.8M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SELF | LITS |
|---|---|---|
| Price | $5.18 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 378.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,530,280.00 | N/A |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $33.87 | ★ N/A |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $4.73 | $0.95 |
| 52 Week High | $5.83 | $3.03 |
Technical Indicators
Market Signals| Indicator | SELF | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 45.03 |
| Support Level | $5.15 | $0.95 |
| Resistance Level | $5.19 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 94.00 | 57.45 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.